AzTrials
AzTrials

Diabetic Foot UlcerMODNCT06729411

Minimal Offloading Dressing for the Treatment of Plantar Diabetes-related Foot Ulcers

A study testing Minimal Offloading dressing and Felted foam in people with Diabetic Foot Ulcer and Offloading, run by Universidad Complutense de Madrid at 1 site in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A monocentre randomized controlled parallel (1:1) clinical trial was performed with consecutively selected individuals with diabetes and active diabetes-related foot ulcers (DFU). Participants were randomly assigned to control or treatment groups. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Diabetic Foot Ulcer, Offloading
What is being tested?
Minimal Offloading dressing and Felted foam
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
40 participants
Where
1 siteSpain
Study dates
1 Dec 2023to 30 Sep 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Type 1 or 2 diabetes mellitus.
  • Age >18 years,
  • Plantar DFU with Texas classification IA or IIA.
  • Glycaemic control confirmed by a haemoglobin A1c ≤ 10% (85.8 mmol/mol) in the previous 3 months.
  • Wound area of 1-30 cm2 at the time of inclusion.

Who cannot join

  • Critical limb ischaemia as defined by the Trans-Atlantic Inter-Society Consensus II guidelines.
  • Active DFU in the contralateral limb, major amputation (below or above the knee) of the contralateral limb.
  • Soft tissue infection.
  • Untreated diabetic foot osteomyelitis.
  • Need for walking aids.

Trial locations and contacts

1 site in 1 country.

Spain1 site
  • Diabetic Foot Unit. Universidad Complutense de Madrid

    Madrid, Madrid, 28040

Other trials in Spain

About this study

Official title: Clinical Efficacy of a Novel Minimal Offloading Dressing for the Treatment of Plantar Diabetes-related Foot Ulcers: A Pilot Randomized Controlled Clinical Trial.

A monocentre randomized controlled parallel (1:1) clinical trial was performed with consecutively selected individuals with diabetes and active diabetes-related foot ulcers (DFU). Participants were randomly assigned to control or treatment groups. The experimental group received MOD treatments, and the control group received 15-mm felted foam treatments. All participants wore a removable ankle-high offloading device.

Primary outcome measure was the 12-week healing rate. The time to healing was evaluated during a 12-week follow-up period. The secondary outcome measures included minor or major amputations related to the DFU during a follow-up period of 6 months.

Read the detailed description

Participants and selection criteria Individuals who met the selection criteria were enrolled consecutively from our specialized outpatient diabetic foot unit. The inclusion criteria were confirmed type 1 or 2 diabetes mellitus, age >18 years, plantar DFU with Texas classification IA or IIA, glycaemic control confirmed by a haemoglobin A1c ≤ 10% (85.8 mmol/mol) in the previous 3 months, and a wound area of 1-30 cm2 at the time of inclusion. The exclusion criteria were critical limb ischaemia as defined by the Trans-Atlantic Inter-Society Consensus II guidelines, active DFU in the contralateral limb, major amputation (below or above the knee) of the contralateral limb, soft tissue infection, untreated diabetic foot osteomyelitis, or a need for walking aids. DFUs related to the lesser toes were excluded from the study due to the different indications for the offloading device.

Peripheral artery disease was confirmed by vascular assessment of the affected foot based on distal pedal pulse palpation, ankle-brachial index, toe brachial index, and transcutaneous oxygen pressure. Critical limb ischaemia was defined as an ankle-brachial index ≤ 0.4 and an ankle systolic blood pressure < 50 mm Hg or a toe systolic blood pressure < 30 mm Hg 13. The characteristics of DFUs were evaluated at baseline.

Interventions Participants were randomly assigned to control or treatment groups. After randomization, all participants were followed for 12 weeks to assess wound healing. Both groups received the same standard of care throughout the trial. The participants visited the outpatient clinic twice weekly, where the DFU was cleaned with sterile normal saline solution and debrided if needed. All wounds were dressed with neutral dressings, depending on the exudate level.

The experimental group received MOD treatments, and the control group received 15-mm felted foam treatments. All participants wore a removable ankle-high offloading device (Stabil-D device, Podartis s.r.l., Crocceta del Montello, Treviso, Italy) and a triple layer bandage to protect the foot shape. The surface of the wound area and photographs were assessed during each monthly visit until the wound healed or the end of the study. Planimetric wound-size measurements were performed by tracing the perimeter on an acetate grid with a fine-nibbed pen using Visitrak (Smith \& Nephew, UK), and digital photographs were taken.

Minimal offloading dressing and felted padding The MOD device was a monolayer device that can be applied directly to the participants skin via a non-irritative adhesive backing. The MOD was made of medium-density ethyl-vinyl acetate (40-45° Shore A hardness and 250-400-kg/cm2 density). The MOD is predesigned for three different locations: the first metatarsal head, central metatarsal heads, and fifth metatarsal. The MOD size ranged from size 35 to 48, which is measured according to the French system for each increase of 6.66 mm in length and 1.5 mm in width. All edges of the MOD were bevelled, and apertures were made to accommodate sites of plantar DFUs.

The felted padding used in the control group was made out of semi-compressed wool felt with an adhesive backing (Herbitas lab, 46134 Foios-Valencia, Spain). The padding thickness was 15 mm on the whole foot, and similar apertures to those used with the other offloading device were made to accommodate the sites of plantar ulceration.

Outcome measures The primary outcome measure was the 12-week healing rate. Healing was defined as intact skin at the foot-ulcer site with complete epithelialization and no drainage. The time to healing was evaluated during a 12-week follow-up period. The secondary outcome measures included minor or major amputations related to the DFU during a follow-up period of 6 months. Delayed wound healing was defined as healing after the 12-week follow-up period. Transfer lesions were defined as a new ulcer located on the same foot secondary to an increase of pressure in areas adjacent to the primary DFU. Finally, adhesive irritation was defined as the presence of erythema and inflammation without the presence of a DFU secondary to contact with the offloading device.

Participants' health-related quality of life (HRQoL) was evaluated using the Diabetic Foot Ulcer Scale - Short Form (DFS-SF). The DFS-SF was applied in personal interviews that were conducted by a trained investigator (MLM). The DFS-SF contains 29 items based on six subscales: leisure, physical health, dependence/daily life, negative emotions, worry about ulcers/feet, and problems with ulcer care. Each item is rated on a 5-point Likert-type scale ranging from 1 ("not at all or none of the time") to 5 ("a great deal, all the time, or extremely"). Individual items on the instrument were reverse coded, and high scores on the DFS-SF indicate a high (good) HRQoL. The score of each subscale was calculated based on a scale of 0 (poorer HRQoL) to 100 (higher HRQoL). Each interview took approximately 15 min. The validated Spanish adaptation of the DFU-SF was used

Being tested
Minimal Offloading dressing, Felted foam
Keywords
diabetic foot, ulcer healing, offloading device, minimal offloading dressing, foot ulcer, healing
Medical subject headings
Diabetic Foot, Foot Ulcer

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Minimal Offloading dressingDevice

    Metatarsal minimal offloading dressings (MODs) are standard offloading devices that are gaining attention. MODs offload a specific ulcerated area and could reduce variability when applying the device onto the skin. MODs are new predesigned devices that do not require any further adaptation or clinician skills and can be directly applied to an ulcerated metatarsal head using a non-irritating adhesive.

  • Felted foamDevice

    The felted padding used in the control group was made out of semi-compressed wool felt with an adhesive backing (Herbitas lab, 46134 Foios-Valencia, Spain). The padding thickness was 15 mm on the whole foot, and similar apertures to those used with the other offloading device were made to accommodate the sites of plantar ulceration.

Study groups in NCT06729411
Study groupRoleWhat they receive
The experimental group received minimal offloading dressing (MOD) treatmentsExperimentalThe MOD device was a monolayer device that can be applied directly to the participants skin via a non-irritative adhesive backing. The MOD was made of medium-density ethyl-vinyl acetate (40-45° Shore A hardness and 250-400-kg/cm2 density). The MOD is predesigned for three different locations: the first metatarsal head, central metatarsal heads, and fifth metatarsal. The MOD size ranged from size 35 to 48, which is measured according to the French system for each increase of 6.66 mm in length and 1.5 mm in width. All edges of the MOD were bevelled, and apertures were made to accommodate sites of plantar DFUs.
Receives: Device: Minimal Offloading dressing
The control group received 15-mm felted foam treatmentsActive comparatorThe felted padding used in the control group was made out of semi-compressed wool felt with an adhesive backing (Herbitas lab, 46134 Foios-Valencia, Spain). The padding thickness was 15 mm on the whole foot, and similar apertures to those used with the other offloading device were made to accommodate the sites of plantar ulceration.
Receives: Device: Felted foam

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Healing rate

    Healing was defined as intact skin at the foot-ulcer site with complete epithelialization and no drainage

    Measured: 12-weeks

Secondary outcomes (3)
  1. Minor amputation

    Any amputation below the ankle

    Measured: 6 months

  2. Major amputation

    Any foot amputation above de ankle, i.e below the knee amputation

    Measured: 6 months

  3. Transfer lesions

    Defined as a new ulcer located on the same foot secondary to an increase of pressure in areas adjacent to the primary DFU

    Measured: 12-weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Dec 2024
  2. Study start1 Dec 2023
  3. Primary completion1 Sep 2024
  4. Study completion30 Sep 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
40 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06729411
Sponsor's protocol ID
MOD_2024
Acronym
MOD
Status last verified
Dec 2024
First submitted
7 Dec 2024
Last updated
17 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: IPD will be shared if asked from any institution

Publications

  • Lazaro-Martinez JL, Garcia-Madrid M, Molines-Barroso RJ, Alvaro-Afonso FJ, Tardaguila-Garcia A, Lopez-Moral M. Clinical Efficacy of a Novel Minimal Offloading Dressing for the Treatment of Plantar Diabetes-Related Foot Ulcers: A Pilot Randomized Controlled Clinical Trial. Adv Skin Wound Care. 2026 Apr 1;39(3):152-158. doi: 10.1097/ASW.0000000000000413. Epub 2026 Feb 19.

    PubMed 41718581

Questions about this trial

What is this clinical trial studying?

A study testing Minimal Offloading dressing and Felted foam in people with Diabetic Foot Ulcer and Offloading, run by Universidad Complutense de Madrid at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Healing rate (time frame: 12-weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06729411, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in